New drug safety check for advanced bladder cancer in india
NCT ID NCT06862219
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is checking the safety of enfortumab vedotin in 100 Indian adults whose bladder cancer has spread or come back after other treatments. Participants receive the drug through an IV every 4 weeks. The main goal is to track side effects, but researchers will also see if the drug shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
enfortumab vedotin
What this could lead to
If successful, this study could confirm that enfortumab vedotin is safe for Indian patients with advanced bladder cancer, supporting its use as a standard treatment option.
What could go wrong
This is a single-arm, open-label safety study with no comparison group, so it cannot prove effectiveness. Side effects like nerve damage, skin reactions, or fatigue may occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site IN91001
RECRUITINGSurat, India
-
Site IN91004
RECRUITINGMumbai, Maharashtra, India
-
Site IN91005
RECRUITINGVaranasi, Uttar Pradesh, India
-
Site IN91006
RECRUITINGKolkata, West Bengal, India
-
Site IN91007
RECRUITINGVellore, Tamil Nadu, India
-
Site IN91008
RECRUITINGMumbai, India
-
Site IN91009
RECRUITINGNagpur, India
-
Site IN91010
RECRUITINGBhubaneswar, India
-
Site IN91012
RECRUITINGAhmedabad, India
-
Site IN91013
RECRUITINGPatna, Bihar, India
-
Site IN91015
RECRUITINGKochi, Kerala, India
-
Site IN91016
RECRUITINGNew Delhi, National Capital Territory of Delhi, India
-
Site IN91017
RECRUITINGDumas, Surat, India